Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Analysts at Jefferies Group increased their FY2017 EPS estimates for shares of Intercept Pharmaceuticals in a research note issued on Wednesday. Jefferies Group analyst M. Yee now expects that the biopharmaceutical company will earn ($13.54) per share for the year, up from their prior estimate of ($14.25). Jefferies Group currently has a “Buy” rating and a $135.00 target price on the stock. Jefferies Group also issued estimates for Intercept Pharmaceuticals’ Q4 2017 earnings at ($3.58) EPS and FY2018 earnings at ($12.38) EPS.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 152.78%. The company had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. During the same quarter in the prior year, the business posted ($3.59) EPS. Intercept Pharmaceuticals’s quarterly revenue was up 697.9% on a year-over-year basis.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/jefferies-group-weighs-in-on-intercept-pharmaceuticals-inc-s-fy2017-earnings-icpt/1681955.html.

Several other brokerages have also commented on ICPT. Cantor Fitzgerald restated an “underweight” rating and set a $69.00 price target (up previously from $60.00) on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Wedbush restated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. BidaskClub raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. Zacks Investment Research raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 price objective for the company in a report on Tuesday, July 11th. Finally, ValuEngine raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Three analysts have rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Intercept Pharmaceuticals currently has an average rating of “Hold” and an average price target of $153.76.

Intercept Pharmaceuticals (ICPT) opened at $65.09 on Monday. The company has a current ratio of 6.61, a quick ratio of 6.61 and a debt-to-equity ratio of 2.05.

In other news, CEO Mark Pruzanski sold 1,532 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Lisa Bright sold 253 shares of the stock in a transaction on Friday, August 25th. The shares were sold at an average price of $111.31, for a total transaction of $28,161.43. Following the completion of the transaction, the insider now owns 23,324 shares of the company’s stock, valued at approximately $2,596,194.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 4,069 shares of company stock valued at $325,974. Corporate insiders own 4.50% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Alps Advisors Inc. raised its stake in shares of Intercept Pharmaceuticals by 9.5% in the 3rd quarter. Alps Advisors Inc. now owns 24,720 shares of the biopharmaceutical company’s stock valued at $1,435,000 after buying an additional 2,147 shares in the last quarter. Birchview Capital LP acquired a new position in shares of Intercept Pharmaceuticals in the 3rd quarter valued at $250,000. IFP Advisors Inc raised its stake in shares of Intercept Pharmaceuticals by 90.9% in the 3rd quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,182 shares in the last quarter. Rothschild Investment Corp IL raised its stake in shares of Intercept Pharmaceuticals by 22.0% in the 3rd quarter. Rothschild Investment Corp IL now owns 5,846 shares of the biopharmaceutical company’s stock valued at $339,000 after buying an additional 1,054 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Intercept Pharmaceuticals by 4.5% in the 3rd quarter. First Trust Advisors LP now owns 300,455 shares of the biopharmaceutical company’s stock valued at $17,438,000 after buying an additional 13,044 shares in the last quarter. Institutional investors own 82.69% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.